These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Watkins RR; Bonomo RA Clin Infect Dis; 2023 May; 76(Suppl 2):S163-S165. PubMed ID: 37125465 [TBL] [Abstract][Full Text] [Related]
7. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Petropoulou D; Siopi M; Vourli S; Pournaras S Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562 [TBL] [Abstract][Full Text] [Related]
8. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant August B; Matlob A; Kale-Pradhan PB Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550 [TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M; Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182 [TBL] [Abstract][Full Text] [Related]
10. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study. Jeon CH; Kim SH; Kim HT; Park KJ; Wi YM J Infect Public Health; 2024 May; 17(5):774-779. PubMed ID: 38518683 [TBL] [Abstract][Full Text] [Related]
13. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334 [TBL] [Abstract][Full Text] [Related]
14. Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections. Howard-Anderson J; van Duin D Antimicrob Agents Chemother; 2021 Oct; 65(11):e0142421. PubMed ID: 34424045 [TBL] [Abstract][Full Text] [Related]
15. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea. Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708 [TBL] [Abstract][Full Text] [Related]
16. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. Katip W; Uitrakul S; Oberdorfer P Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359 [TBL] [Abstract][Full Text] [Related]
18. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385 [TBL] [Abstract][Full Text] [Related]